Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Bristol Myers Squibb acquisition of Forbius
Davis Polk is advising Bristol Myers Squibb on its acquisition of Forbius. The transaction includes an upfront payment and…
CureVac $245.3 million IPO
Davis Polk advised CureVac N.V. on its $245.3 million initial public offering of 15,333,332 of its common shares, which…
Five Prime Therapeutics $75 million at-the-market offering
Davis Polk advised the sales agent on the SEC-registered at-the-market offering by Five Prime Therapeutics, Inc. of its…
Personalis $125 million stock offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters on the $125 million…
IDEAYA Biosciences $50 million at-the-market offering
Davis Polk advised the sales agent on the SEC-registered at-the-market offering by IDEAYA Biosciences, Inc. of its…
Atreca $100 million at-the-market offering
Davis Polk advised the sales agent on the SEC-registered at-the-market offering by Atreca, Inc. of its common stock for up…
Freeline Therapeutics Holdings $158.8 million IPO
Davis Polk advised Freeline Therapeutics Holdings plc on its $158.8 million initial public offering of 8,823,529 American…
Horizon Therapeutics $963.5 million share offering
Davis Polk advised the representatives of the underwriters in connection with an approximately $963.5 million public…
Acutus Medical $170 million IPO
Davis Polk advised Acutus Medical, Inc. on its SEC-registered initial public offering of 10,147,058 shares of common stock…
Oak Street Health $377.3 million IPO
Davis Polk advised the joint book running managers in connection with the $377.3 million initial public offering of 17,968…